Browse the evidence

Retatrutide administered at a 12 mg dosage resulted in significant reductions in body weight, body mass index, and waist circumference.

Practitioners can consider retatrutide as an effective treatment option for obesity.

A higher percentage of patients receiving retatrutide achieved weight losses of ≥5%, 10%, 15%, and 20% compared to placebo.

Retatrutide may be particularly effective for patients aiming for significant weight loss.

Efsubaglutide Alfa produced a mean weight reduction of 7.16% versus 0.86% with placebo.

Efsubaglutide Alfa may be an effective treatment option for weight loss in individuals with obesity or overweight.

82.5% of Efsubaglutide-treated participants achieved ≥5% weight loss.

A significant proportion of individuals treated with Efsubaglutide Alfa can expect to achieve clinically meaningful weight loss.

Cagrisema produced significantly greater percentage weight loss than semaglutide with a mean difference of -7.47% (95% CI: -10.58, -4.36; p < 0.001).

Cagrisema may be a more effective option for weight loss in obese patients compared to semaglutide.

Cagrilintide monotherapy weight loss was comparable to semaglutide.

Cagrilintide may be a viable alternative to semaglutide for weight management in obese patients.

Cagrisema is safe and has a comparable side effect profile to semaglutide.

Cagrisema can be considered a safe option for weight management in obese patients.

A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group compared to 22.4% in the placebo group.

Semaglutide may help reduce liver fibrosis in patients with MASH.

The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.

Semaglutide may lead to significant weight loss in patients with MASH.

Higher weight loss was associated with a lower hazard of discontinuation for both patients with and without type 2 diabetes.

Encouraging weight loss may improve adherence to GLP-1 RA therapy.

Tirzepatide (15 mg once weekly) resulted in weight loss of up to 17.8% after 72 weeks of therapy.

Tirzepatide is an effective option for weight loss in adults without diabetes.

Semaglutide (2.4 mg once weekly) resulted in weight loss of up to 13.9% after 68 weeks.

Semaglutide is a viable weight loss treatment for adults without diabetes.

GLP-1 receptor agonists and co-agonists are efficacious for weight loss with safety concerns predominantly gastrointestinal.

Practitioners should consider GLP-1 RAs for weight management, noting gastrointestinal side effects.

Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.

Practitioners can consider cagrilintide-semaglutide as an effective treatment for weight management in this population.

More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more.

Cagrilintide-semaglutide may be particularly effective for achieving clinically significant weight loss.

The percentage of patients who had a glycated hemoglobin level of 6.5% or less was significantly higher in the cagrilintide-semaglutide group compared to the placebo group.

This treatment may significantly improve glycemic control in patients with type 2 diabetes.

Semaglutide 2.4 mg weekly significantly reduces Major Adverse Cardiovascular Events (MACE) in obese patients without type 2 diabetes, independent of the magnitude of weight loss.

If you have obesity (BMI ≥ 27) but no diabetes, weekly semaglutide (2.4 mg) is a proven therapy to significantly lower your risk of heart attack, stroke, and cardiovascular death. This benefit happens through direct protection of your blood vessels and reduction of inflammation, not just by making you lose weight. To get the best results, you must pair the medication with a gradual dose increase to minimize stomach issues, and you must actively engage in resistance training and eat enough protein to prevent muscle loss.

GLP1-RA treatment is associated with improvements in restrained eating and emotional eating behavior compared with placebo.

GLP1-RAs may help improve eating behaviors in this population.

In the obesity cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -12.3% to -16.2%, compared to -2.5% with placebo.

Maridebart cafraglutide may be an effective treatment option for weight loss in individuals with obesity.

In the obesity-diabetes cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -8.4% to -12.3%, compared to -1.7% with placebo.

Maridebart cafraglutide may also be effective for weight loss in individuals with obesity and type 2 diabetes.

A diet that recapitulated key characteristics of non-industrialized dietary patterns improved gut microbiome interactions and provided cardiometabolic benefits.

Practitioners may consider recommending dietary patterns that mimic non-industrialized diets to improve gut health and cardiometabolic outcomes.

Tirzepatide would avert 45,609 obesity cases per 100,000 individuals over a lifetime.

Tirzepatide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Semaglutide would avert 32,087 obesity cases per 100,000 individuals over a lifetime.

Semaglutide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Metabolic bariatric surgery (MBS) was associated with greater total weight loss (mean 28.3%) compared to GLP-1 receptor agonists (mean 10.3%) in patients with class II and III obesity.

MBS may be a more effective option for significant weight loss in patients with higher obesity classes.